UNSPSC 51151537: Benzpyrinium bromide

This classification denotes a cholinergic agonist with the molecular formula C15H17N2O2.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0L78YB79M, chemically known as pyridinium, 3-((dimethylaminocarbonyl)oxy)-1-(phenylmethyl)-, bromide but more generally known as benzpyrinium bromide, which bears US NIH Compound Identifier 11481. European Medicines Agency schedules Benzpyrinium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05766MIG.

UNSPSC 51151537 Benzpyrinium bromide is a Commodity code that captures pharmaceutical and chemical compounds used in health and safety applications. Recent state and local solicitations under this code reflect procurement of naloxone (an opioid antagonist) and related drug deactivation systems for public health initiatives, alongside exploratory vendor outreach for direct-to-manufacturer pharmaceutical supply models. The code serves county health departments, state human services agencies, and other public health entities that source pharmaceuticals and related products to support community health and emergency response programs. Issuing bodies soliciting under this code include county-level health and procurement offices as well as state health and human services commissions.

Activity appears concentrated in the Southeast and Southwest, with documented recent opportunities in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, under a two-year initial term with a one-year renewal option; responses were due July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, representing a preliminary market-intelligence phase prior to formal competitive solicitation. The Florida opportunity specifies E-Verify compliance, drug-free workplace certification, and standard commercial insurance requirements, while the Texas RFI does not specify set-asides or disadvantaged-enterprise restrictions.